Novartis reports zero impact of Cosentyx on moderate to severe plaque psoriasis
Two thirds of patients on Cosentyx (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows
Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin disease on their quality of life through 5 years, as described by the Dermatology Life Quality Index (DLQI) 0/1 response (72.7% at Year 1 and 65.5% at Year 5) – a questionnaire used to evaluate the impact of skin disease on a patient’s quality of life.
Study findings also show absolute PASI ≤1/≤2/≤3 responses at Year 1 (58.6%, 67.9% and 74.1%, respectively) were sustained to Year 5 (53.3%, 66.4% and 75.4%, respectively); as observed analysis.Absolute PASI scores can provide an indication of disease severity after treatment. Achievement of an absolute PASI score lower than 2 or 3 has been proposed as an indication of treatment success.
Craig Leonardi, MD, Adjunct Professor of Dermatology at St. Louis University School of Medicine said “Results from the SCULPTURE study show treatment with Cosentyx can deliver both over the long-term. It’s encouraging to see such improvements in DLQI responses and absolute PASI scores below 3 through 5 years.”
Chronic adverse events included nasopharyngitis, upper respiratory tract infection and headache, consistent with those reported in the core study and previous Phase III studies.